Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 55/100

Termination Rate

10.0%

1 terminated out of 10 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

7Total
Not Applicable (3)
P 3 (1)
P 4 (3)

Trial Status

Recruiting6
Unknown3
Terminated1

Clinical Trials (10)

Showing 10 of 10 trials
NCT06079021Not ApplicableRecruiting

COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device

NCT03297281Not ApplicableRecruiting

Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)

NCT04556188Recruiting

The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa

NCT06108414Phase 4Recruiting

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

NCT06401616Phase 4Recruiting

Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)

NCT06187311Phase 4Recruiting

Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

NCT06144866Unknown

Evaluataion of NOAC Levels in Acute Stroke

NCT05332158Not ApplicableUnknown

Medicines Gaps Study

NCT04056143UnknownPrimary

Precision Medicine Platform for Novel Oral Anticoagulants

NCT03926156Phase 3Terminated

RIvoraxaban in Mitral Stenosis

Showing all 10 trials

Research Network

Activity Timeline